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INTRODUCTION
Basal cell carcinoma (BCC) is the most common malignancy in the Caucasian population. 
It accounts for around 80% of all non-melanoma skin cancers (NMSC). It is typically slow 
growing and rarely metastatic but its location, tendency to relapse, multiplicity and 
possibility to invade and destroy local tissues1 delimit disease morbidity. Surgical 
approaches are the standard strategy for well-defined BCC. Mohs micrographic surgery 
is generally applied to high-risk tumors or those tumors placed in cosmetically sensitive 
areas whereas cryotherapy or electrodessication and curettage (EDC) are acceptable 
treatment options for small size superficial BCC (sBCCs) in the trunk and limbs. However, 
for patients who are poor candidates for surgery, or have low-risk BCC, as is the case of 
sBCC, non-surgical methods such as topical treatment or photodynamic therapy may be 
alternative treatment options which may also reduce the risk of scarring compared to 
the surgical approach.2, 3
Among some already known topical treatments such as 5-fluoracil cream and imiquimod 
gel, topical ingenol mebutate gel (PEP005), a diterpene ester extracted from the plant 
Euphorbia Peplus, is only approved for actinic keratosis treatment. In actinic keratosis, 
IMG 0.05% is applied once daily for 2 consecutive days in affected areas of 25 cm2 of the 
trunk and limbs. IMG has demonstrated therapeutic effects on various cutaneous 
neoplasms including warts, corns, and cancerous lesions4. Although IMG is not 
considered the first option for the treatment of BCC; there is some evidence supporting 
its efficacy and safety4-11. In a phase II randomized study, 60 patients with sBCC were 
placed on varying dosing regimens and concentrations of either IMG or the gel vehicle. 
Significant histologic clearance at 85 days post-treatment was observed in 63% of 
patients when 0.05% IMG was applied for two consecutive days (p<0.031)5.
IMG induces mitochondria swelling of dysplastic keratinocytes and cell death by primary 
necrosis. Topical application generates neutrophilic infiltration due to protein kinase C 
activation, causing effective wound healing. Its dual mechanism of action is 
characterized by a rapid necrosis lesion beginning 1 to 2 hours after application (causing 
an increase of intracellular calcium, mitochondrial swelling, and loss of cells membrane 
integrity) followed by tumor cell apoptosis via neutrophil-mediated cellular cytotoxicity 
occurring within days. At this time, there is also an increase of TNF-α and IL-8, which 
recruits and subsequently activates neutrophils towards the inflammatory infiltrate12. 
However, the exact mechanism of action of IMG has not been fully elucidated.
Here, we describe our experience using topical treatment IMG, 0.05% under occlusion 
in a group of patients with BCC in low-risk locations (trunk and limbs). Our aim was to 
assess the efficacy and safety of IMG in this indication but also to characterize the 
inflammatory cell infiltration at different timepoints to better understand IMG’s 
mechanism of action. To our knowledge, this is the first study that, beyond clinical 





























































evaluation, analyses the immunoinflammatory infiltrate post IMG treatment in BCC 
tumors.
MATERIALS AND METHODS
Between May and September 2015, a prospective, parallel, interventional, and 
randomized clinical study on the efficacy of IMG in BCC was conducted. Twenty one 
patients were chosen for the screening visit of which five of them were excluded due 
to incorrect treatment compliance: a total of 16 BCC patients were included. Inclusion 
criteria was: Caucasian adults above 18 years of age with a histologically confirmed 
primary BCC (superficial, nodular or infiltrating histological subtypes defined in 
accordance with published criteria2), located in low risk zones (trunk and limbs) with 
an extension up to 1 cm2. Exclusion criteria was: pregnant and breast feeding women, 
immunocompromised patients, genetic predisposition to BCC or recurrent BCCs. The 
study was approved by the Independent Ethics Committee at the Hospital Universitari 
Arnau de Vilanova de Lleida, Spain.
Informed consents and samples from patients were obtained with support from IRB 
Lleida Biobank (B.0000682) and PLATAFORMA BIOBANCOS (PT13/0010/0014). Biobank 
is an authorized institution of the Health Department of Catalonia as from the 29th of 
April, 2013 and registered in the National Register of Biobanks of the Carlos III Health 
Institute (Spain). The Biobank guarantees the traceability and quality of the samples, 
plus the consent process undertaken in accordance with the protocols approved by the 
Local Ethical Committee, following the basic principles (respect for the individual), 
operational risk-management (risk-benefit) and guidelines (good clinical practice) of the 
Declaration of Helsinki (World Medical Association, 1964).
IMG 0.05% was applied on the lesion site and on a 1 cm perimeter surrounding the 
lesion site, once daily for two consecutive days. Considering BCC as more locally 
invasive than actinic keratosis, we applied the gel under occlusion with aluminum 
disks. Lesions were observed in the following days after treatment according to 
randomization groups: biopsies were taken between the third and the tenth day after 
treatment initiation in the first group as an ‘early immune response model’, coinciding 
with the maximum clinical inflammation (10 patients, Group 1) and the second group 
was biopsied at day 30 after treatment initiation as a ‘late immune response model’ (6 
patients, Group 2); (Fig. 1).
Control samples consisted of five biopsies obtained from both groups before starting 
IMG application (untreated samples). Treatment efficacy was assessed in terms of
clinical and histological complete response. We used the local skin reaction (LSR) grading 
scale to describe side effects related to therapy11.This scale is based on a 0–4 numerical 





























































index (being 4 the highest grade of severity) related to 6 specific clinical parameters 
(erythema, scaling, crusting, swelling, and vesiculation/pustulation, erosion/ulceration) 
accompanied by a characteristic photographic image for each rating. Total LSR (Local 
Skin Reaction) score ranges from 0 to 24 points13. The LSR test was evaluated one week 
after treatment initiation for every patient. Pictures were also taken in every patient at 
the screening visit, before treatment initiation, and during the follow up visits depending 
on each arm. Patients were randomized into group 1 and group 2 according to whether 
the inclusion visit was an even or odd day. An additional follow up after 3 months, 6 
months, 1 year, and 2 years after treatment was conducted in every case. Patients with 
no tumor clearance in the follow-up biopsies discontinued the study and any remaining 
tumor was treated by surgery short time later.
Immunohistochemical study
Histopathological changes including necrosis and type and degree of the inflammatory 
infiltrate were analyzed by a semiquantitative measurements. 
All post-treatment biopsies and the 5 screening biopsies (control) were analyzed by 
immunohistochemistry with different antibodies: antiCD3, -CD4, -CD8, -CD20, -CD56, -
CD68, -Bcl-2, -CASP3, -FoxP3, -GrzB and -TIA1. See Table 1. 
Tissue blocks were sectioned at 3 μm-thickness, dried for 1 hour at 65ºC before pre-
treatment procedure of deparaffinization, rehydration and epitope retrieval in the pre-
Treatment Module, PT-LINK (DAKO) (at 95ºC for 20 min in 50 x Tris/EDTA buffer and 
pH 9). Before staining, endogenous peroxidase activity was blocked with peroxidase 
blocking solution (Dako, Glostrup, Denmark). After incubation with primary antibodies, 
the reaction was visualized with the EnVisionTM FLEX Detection Kit (DAKO, Glostrup, 
Denmark) using diaminobenzidine chromogen as a substrate 
according to manufacturer’s instructions. Sections were counterstained with 
hematoxylin. Primary antibodies used in this study are listed in Table 1.
All tissue samples were histologically reviewed by 2 blinded members of the team. For 
the staining scoring, an automated imaging system, the ACIS® III Instrument (DAKO, 
Denmark, Glostrup), was used. The mean percentage of positive cells was obtained after 
evaluating regions of interest coincident with areas of higher infiltration.
Immunohistochemical post-treatment results were normalized by a control group and 
were analyzed by ANOVA statistical test.
RESULTS
Efficacy and safety of IMG 0.05% under occlusion in BCC
A total of sixteen patients were included in the study. Clinical and tumor baseline 
variables are shown in Table 2. The majority of patients were women (62.5%) with a 





























































mean age of 66 and more than half of the lesions were located in the trunk (56.25%). 
There were ten superficial BCCs, five nodular BCCs and one infiltrative BCC.
After treatment, complete tumor clearance was observed in 8/10 (80%) sBCC, 2/5 (40%) 
nodular BCCs and 0/1 (0%) infiltrative BCC. Overall, 10 tumors were cleared which did 
not show any evidence of recurrence after a 2-year follow-up.
Regarding adverse events, 10/16 (62.5%) patients experienced a significant local 
inflammatory reaction with marked tumor erosion and the LSR grading scale was over 
20. Four out of sixteen (25%) patients had medium LSR score (values between 12-18) 
and 2/16 (12.5%) patients had low LSR score (LSR score < 8). Interestingly, patients with 
medium or low values in LSR score did not show clinical nor histological clearance.
The first day of treatment, some patients experienced severe pain and 
flaking/blistering/erythema extending beyond the application site (Fig. 2). From the 
third day, pain was gradually relieved (with all symptoms disappearing after 1 week) and 
an erosive patch developed after blister rupture (Fig. 3).
At the end of treatment (days 3 to 5), erythema was present in 100% of BCCs and 
erosions and bulla were present in 10/16 of the cases. LSRs lasted about 2 weeks and 
we observed almost complete resolution after 5 weeks from treatment initiation. No 
systemic features as headache or malaise were reported.
Overall, this study showed that 10/16 (62.5%) patients were in complete remission after 
2 years of follow-up. LSRs started the first day of treatment but resolved almost 
completely after 5 weeks. 
Histopathology
An important epithelial and superficial dermal necrosis was observed in biopsies taken 
from Group 1 accompanied by an important inflammatory cell infiltration mainly 
composed of polymorphonuclear (PMN) cells (Fig. 4) and some mononuclear cells. 
Necrosis degree and inflammatory infiltrate in group 2, were lower than in group 
1. In biopsies taken at day 30 after treatment initiation (Group 2) necrosis degree and 
inflammatory infiltrate were lower than in Group 1, and necrosis was replaced by 
fibrosis although a mild-moderate mononuclear cell infiltration was still evident in most 
of the samples (Fig. 4). Regarding the adaptive immune response, a similar pattern was 
observed. A high increase of CD3+ cells was observed at early timepoints (p=0.013 
compared to control), mainly composed by cytotoxic CD8+ and CD4+ T cells (p=0.16 and 
p=0.016 respectively compared to control). T cell recruitment also decreased over time, 
but while CD4+ T cells returned to control levels at day 30 after treatment initiation 
(group 2), residual presence of CD8+ T cells was observed although not statistically 
significant. These results suggest that some cytotoxic activity was present at the BCC 
zone at late timepoints considering the presence of CD8+ T cells and NK (CD56+) within 
the infiltrate. Moreover, remaining expression of TIA-1 (cytotoxic marker) was also 
observed.





























































Reduction of T-cell recruitment in the late immune response coincided with a high 
presence of regulatory T cells (Tregs); FoxP3+ in situ cells. This subpopulation suppresses 
effector T cells activity (CD4+ and CD8+). There was also some B-cell recruitment (CD20) 
possibly induced later in the immune response cascade compared with effector T-cell
recruitment and remaining for longer time. Although this tendency, presence of both 
cell subtypes is not statistically significant (data not shown; Fig. 6).
Regarding apoptotic markers, we observe a high expression of active caspase 3 and 
granzyme B at early timepoints (p=0.13 and p=0.06 respectively compared to control) 
whereas the levels of the transcription factor Bcl-2an antiapoptotic marker, were lower 
in group 2 than in group 1, reaching lower levels than in control samples. This apoptosis 
might be induced to stop the immune response from all recruited inflammatory cells 
once the tumor is cleared. (Fig. 5, 6).
DISCUSSION
The incidence of non-melanoma skin cancers is undergoing a drastic global increase. The 
continuous search for non-invasive treatments has encouraged the development of new 
therapeutic agents. An understanding of the history, mechanism of action, and recent 
trial evidence for emerging therapies may help physicians in counseling patients on 
available treatment options and to select the appropriate therapy 7,8.
In this study we demonstrated the efficacy of IMG 0.05% in BCC under occlusion, 
especially for the superficial subtype, where 80% of the cases achieved complete 
remission and maintained this response after 2 years of follow-up.
Published clinical trials where sBCC were treated with IMG show similar or lower 
response rates: in a phase II randomized study, 60 patients with sBCC were placed on 
varying dosing regimens and concentrations of either IMG or the gel vehicle. Significant 
histologic clearance at 85 days post-treatment was observed in 63% of patients when 
0.05% IMG was applied for two consecutive days (p<0.031)5. In a phase I/II clinical study, 
82% of patients who failed or refused conventional treatment for sBCC achieved a 
complete clinical response one month after Euphorbia peplus treatment and 57% 
continued after a mean follow-up of 15 months6.
Safety profile in those trials was favorable with mild to moderate adverse events 
including erythema, flaking, scaling, erosion, and ulceration. LSRs appeared to be dose-
dependent and developed rapidly after application (within the first day), peaked in 





























































severity shortly after the end of the treatment (one week) and returned to near baseline 
levels within two weeks5.
There are also some other case reports7 and short patient series with BCC, treated with 
different IMG posology (0.015 or 0.05%), time length and number of cycles with 
complete clearance outcomes 5-10.
The main difference between our study and those reported in the literature is the use 
of IMG under occlusion; it may be the reason why we obtained higher rates of complete 
response in sBCC. High efficacy of IMG 0.05% under occlusion has already been shown 
in a short series (n=7) where patients with sBCC in the trunk achieved complete response 
within 2 to 4 weeks10.
Apart from sBCC cases, our study included other BCC subtypes (superficial, nodular or 
infiltrating histological subtypes). The results indicate that 2/5 (40%) nodular BCC 
resolved whereas none (0/1; 0%) of the infiltrative BCC had a successful response. We 
may conclude that IMG under occlusion was more efficacious in treating sBCC rather 
than other subtypes despite the limitation of having collected very low number of 
lesions. To our knowledge there is not much evidence of nodular or infiltrative BCCs 
treated with IMG reported in the literature. More studies should be done in order to 
reach stronger conclusions about the use of IMG in those BCC subtypes. Overall, our 
study showed that 10/16 (62.5%) of patients obtained complete remission after 
treatment.
We would like to highlight that 2/5 patients that were withdrawn from the study due to 
incorrect treatment compliance, had tumor residues confirmed by biopsy. However, 
some weeks later, when those skin lesions were about to be removed by surgery, no 
tumor was detected at that time. In some cases, the immune system may take longer to 
completely destroy the tumor since patients that were considered as non-complete 
responders actually were complete responders. We hypothesize that this finding may 
correlate with our observation that some cytotoxic cells remained at the tumor site even 
30 days after treatment initiation, meaning that some cytotoxic activity may be present 
at the late immune response timepoint, even after LSRs resolution.
Regarding safety, we observed remarkable adverse events in 10/16 (62.5%) of the 
patients. Erythema and blister formation started within the first day of treatment and 
an extensive necrosis was present at day 3 after treatment initiation concurring with a 
high inflammatory response. IMG produces a non-specific epidermal and superficial 
dermal necrosis at the very beginning leading to a release of the cytosolic components 
within the tumor site, acting as antigens triggering the activation of both the innate and 
the adaptive immune responses. This papillar dermal necrosis produced by occlusive 
treatment may be responsible for scarring in some patients and might also be the reason 
why we observed longer duration of LSRs in our patients compared to other studies 





























































found in the literature. It is also important to notice that 6 patients with medium or low 
LSR score did not show tumor regression, suggesting that an incomplete immune 
response is unable to induce tumor clearance.
Regarding cell recruitment at tumor site, in terms of innate response we observed a high 
neutrophilic infiltration (PMN) reinforced by macrophages (p=0.03) and NK cells (even if 
not statistically significant). 
In terms of adaptive immune response, we observed an important recruitment of T-cells 
(lymphocytes): CD4+ (p=0.016) and CD8+ (non statistically significant) at early 
timepoints. Interestingly, CD4+ T cells return to control levels whereas the recruitment 
of NK cells, CD8+ T cells, and the presence of TIA-1 show that some cytotoxic activity 
may remain within the tumor site at late immune response timepoints. 
There is also a high expression of active caspase 3 and granzyme B at early timepoints 
(10 days after treatment initiation; data not shown), at the same time when we 
observed an increase of Tregs cells; a T-cell subpopulation able to downregulate and 
suppress T effector cells by several mechanisms, including apoptosis. The real 
mechanism of action of Tregs cells has not been fully elucidated14, but Tregs cells may 
induce the apoptotic activity to decrease the recruitment and activity of T effector cells 
(CD4+ and CD8+) as we observe. 
Similar results were obtained in a phase I randomized trial in which 26 patients with 
actinic keratosis were treated with IMG 0.05%. One day after treatment initiation, 
inflammatory cell infiltration was dominated by CD4+ and CD8+ T cells as well as 
neutrophils and macrophages within both dermis and epidermis. Fewer changes were 
observed for CD20+ B-cells which might be produced later, as we observed in our study. 
Apoptosis (caspase 3) was also found at early timepoints after treatment.15
Overall, we found that ingenol mebutate gel was an effective drug to treat basal cell 
carcinoma, especially the superficial subtype. Necrosis reaction accompanied by both 
innate and adaptive immune cells recruitment mainly occurring at early response 
timepoints after treatment initiation may be responsible for the observed efficacy rates. 
Cytotoxic markers observed at late response timepoints may ensure complete response 
by destroying residual tumor cells. Further research about the ingenol mebutate 
mechanism of action needs to be done.
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Figure 1. Study design (timing and assessment visits). 




















































































































GrB-7 M7235 1:50 DAKO, Glostrup, Denmark
Cytotoxicity marker
TIA1 TIA-1 Ab2712 1:100 Abcam, Cambridge, UK
Natural killers  and 
cytotoxic 
lymphocytes
Table 1. Primary antibodies used in the study to evaluate inflammatory cell infiltration in groups 
1 and 2 after treatment with IMG.





























































Table 2. Clinical and pathological data from the 16 patients with BCC included in the 
study.





























































Figure 2. Local skin reaction after IMG treatment. (a) Nodular BCC in lower limbs.  (b) Clinical 
reaction after 3 days from treatment initiation. Note the extending erythema with an important 
blister in the middle which produced severe pain to the patient. (c) Clinical appearence 30 days 
from treatment initiation (group 2). (d) Clinical appearence after 6 months of follow up; no 
evidence of recurrence was detected but a residual hiperpigmentation and a scar were 
observed. 





























































Figure 3. Follow up of a patient treated with IMG. (a) Superficial BCC in the back at baseline. 
(b) An erosive patch after blister rupture was observed 10 days after treatment. (c) Residual 
erythema after 2 months of treatment initiation. (d) Residual scar after 6 months of follow up.





























































Figure 4. Representative samples showing different degrees of necrosis according to 
the timepoint when biopsies were collected. (a,b) Relevant epidermal and dermal 
necrosis appearing in certain areas reaching the middle dermis after 3 days from 
treatment initiation with IMG were observed. Image (a) emphasizes a huge sub-
epidermal blister while image (b) emphasizes the intense neutrophilic infiltrate 
accompanied by an important inflammatory cell infiltration mainly composed by 
polymorphonuclear cells. (c) Reduction of necrosis and the intensity of the immune cell 
infiltration were observed 10 days after treatment initiation with IMG. Some tumor 
areas were still present. (d) Day 30 post-treatment biopsy. A residual immune cell 
infiltration and fibrosis tissue were observed. Original magnification: (a,b,c) Hematoxylin 
and eosin (4X); (d)  Hematoxylin and eosin (10X).





























































Figure 5. Bar chart with the results of all analyzed markers. ANOVA statistical test, * =P<0.05.





























































Figure 6. Representative samples showing immunohistochemistry results in the control 
samples and in the different groups. (a) Control samples. (b)  Group 1(early immune response). 
(c) Group 2 (late immune response).
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Table 2. Clinical and pathological data from the 16 patients with BCC included in the 
study.
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